Research output per year
Research output per year
Personal profile
Biography
Dr Anna Kemp-Casey has worked with the Centre for Health Services at The University of Western Australia since 2007. Her primary research interest is medicines utilisation and medicines policy. Her other research activities are the analysis of whole-population prescription and linked health data. She has trained jundreds of researchers, policy makers and clinicians to analyse Pharmaceutical Benefits Scheme and Medicare Benefits Schedule data for health research.
Roles and responsibilities
Former Member, Drug Utilisation Sub Committee of the Pharmaceutical Benefits Advisory Committee
Research Advisor, Population Health Research Network (PHRN) Proof of Concept (PoC) Reference Group
School of Population Health Consumer and Community Advisory Council
Research Advisor, Population Health Research Network (PHRN) Proof of Concept (PoC) Reference Group
School of Population Health Consumer and Community Advisory Council
Funding overview
Roughead E, Ryan P, Graves S, Pratt N, Shakib S, Caughey G, Huang N, Kemp A. Centre of excellence in post-marketing surveillance of medicines and devices. NHMRC Centre for Research Excellence 2013-2017: $2.5 million.
Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D. Pharmacotherapy for smoking cessation during pregnancy and the inter-pregnancy period: a population-based cohort study. NHMRC Project Grant 2012-2016: $620,950.
Preen D, Roughead L, Saunders C, Kemp A, Bulsara M, Holman CDJ. Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian clinical practice. Cancer Australia 2011-2013: $466,498 (2011 $193,070; 2012 $136,714; 2013 $136,714).
Preen DB, Kemp A, Briffa T, Sanfilippo FM, Morlet N. Does treatment of age-related macular degeneration with intravitreal injection of vascular endothelial growth factor inhibitors increase arterial thromboembolic events? NSW Save Sight Institute, 2011: $53,764.
Kemp A, Ng J, 2009, '2010 - Does Treatment of Age-Related Macular Degeneration with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors Increase Arterial Thromboembolic Events?', UWA Research Development Award Scheme, Funds Approved: $29,579.00.
Havard A, Jorm L, Preen D, Daube M, Kemp A, Einarsdottir K, Randall D. Pharmacotherapy for smoking cessation during pregnancy and the inter-pregnancy period: a population-based cohort study. NHMRC Project Grant 2012-2016: $620,950.
Preen D, Roughead L, Saunders C, Kemp A, Bulsara M, Holman CDJ. Endocrine therapies for early breast cancer: health outcomes and policy implications in Australian clinical practice. Cancer Australia 2011-2013: $466,498 (2011 $193,070; 2012 $136,714; 2013 $136,714).
Preen DB, Kemp A, Briffa T, Sanfilippo FM, Morlet N. Does treatment of age-related macular degeneration with intravitreal injection of vascular endothelial growth factor inhibitors increase arterial thromboembolic events? NSW Save Sight Institute, 2011: $53,764.
Kemp A, Ng J, 2009, '2010 - Does Treatment of Age-Related Macular Degeneration with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors Increase Arterial Thromboembolic Events?', UWA Research Development Award Scheme, Funds Approved: $29,579.00.
Previous positions
Deputy Chair, Faculty of Medicine, Dentistry and Health Sciences Regional Human Research Ethics Committee.
Visiting Research Fellow, The Sax Institute, Sydney.
Visiting Research Fellow, Illawarra Health and Medical Research Institute, University of Wollongong.
Visiting Research Fellow, The Sax Institute, Sydney.
Visiting Research Fellow, Illawarra Health and Medical Research Institute, University of Wollongong.
Current projects
Endocrine therapy for early breast cancer: utilisation and outcomes in Australian practice.
Research
Impact of Pharmaceutical Benefits Scheme (PBS) policy changes on utilisation of prescription medicines and health services, utilisation of endocrine therapies for breast cancer, utilisation of opioids, analysis of linked health datasets
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD
Award Date: 1 Aug 2007
External positions
Research Fellow, University of South Australia
Research expertise keywords
- Pharmacoepidemiology
- Health record linkage
- Cost barriers to medicine use
- Health services research
- Pharmaceutical Benefits Scheme (PBS) data
- Medicare Benefits Schedule (MBS) data
- Australian pharmaceutical policy
- Hormone therapies for breast cancer
Fingerprint
Dive into the research topics where Anna Kemp-Casey is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
-
Are assisted reproductive technology pregnancies more likely to be exposed to teratogenic medication? A whole-population study
Kemp-Casey, A., Hart, R., Milne, E., Bower, C., Walls, M. L., Yovich, J. L., Burton, P., Liu, Y., Barblett, H. & Hansen, M., 9 Dec 2024, (E-pub ahead of print) In: Australian and New Zealand Journal of Obstetrics and Gynaecology. 8 p.Research output: Contribution to journal › Article › peer-review
-
Ovulation induction and subfertile untreated conception groups offer improved options for interpreting risks associated with ART
Hansen, M., Hart, R. J., Milne, E., Bower, C., Walls, M. L., Yovich, J. L., Burton, P., Liu, Y., Barblett, H. & Kemp-Casey, A., Apr 2024, In: Journal of Assisted Reproduction and Genetics. 41, 4, p. 915-928 14 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
The Australian Genetic Heart Disease Registry: Protocol for a Data Linkage Study
Butters, A., Blanch, B., Kemp-Casey, A., Do, J., Yeates, L., Leslie, F., Semsarian, C., Nedkoff, L., Briffa, T., Ingles, J. & Sweeting, J., 2 May 2023, In: JMIR Research Protocols. 12, e48636.Research output: Contribution to journal › Article › peer-review
Open Access -
Exploring the association between stroke and acute myocardial infarction and statins adherence following a medicines co-payment increase
Seaman, K. L., Bulsara, M. K., Sanfilippo, F. M., Kemp-Casey, A., Roughead, E. E., Bulsara, C., Watts, G. F. & Preen, D. B., Oct 2021, In: Research in Social and Administrative Pharmacy. 17, 10, p. 1780-1785 6 p.Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
Impact of an Australian/New Zealand organisational position statement on extended-release opioid prescribing among surgical inpatients: a dual centre before-and-after study
Awadalla, R., Liu, S., Kemp-Casey, A., Gnjidic, D., Patanwala, A., Stevens, J. A., Begley, D., Bugeja, B. & Penm, J., Dec 2021, In: Anaesthesia. 76, 12, p. 1607-1615 9 p.Research output: Contribution to journal › Article › peer-review
14 Citations (Scopus)
Projects
- 4 Finished
-
Evaluation of the Medibank Health Solutions Integrated Health Care Services Model of Care Initiative
Preen, D. (Investigator 01), Kemp-Casey, A. (Investigator 02) & Li, I. (Investigator 03)
1/07/15 → 31/12/17
Project: Research
-
Recent changes in IVF clinical practice: data linkage to investigate their impact on fetal growth and birth defects
Hansen, M. (Investigator 01), Hart, R. (Investigator 02), Milne, E. (Investigator 03), Kemp-Casey, A. (Investigator 04) & Charles, A. (Investigator 05)
NHMRC National Health and Medical Research Council
1/01/15 → 31/12/19
Project: Research
-
Vascular endothelial growth factor inhibitors and cardiovascular events in the treatment of neovascular age-related macular degeneration
Preen, D. (Investigator 01), Kemp-Casey, A. (Investigator 02), Briffa, T. (Investigator 03) & Sanfilippo, F. (Investigator 04)
1/01/11 → 31/12/11
Project: Research
-
2010 - Does Treatment of Age-Related Macular Degeneration with Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors Increase Arterial Thromboembolic Events?
Kemp-Casey, A. (Investigator 01), Morlet, N. (Investigator 02) & Ng, J. (Investigator 03)
The University of Western Australia
1/01/10 → 31/12/10
Project: Research